Wolchko J Scott's Form 4 filing
Fate Therapeutics Inc (FATE) · filed Apr 25, 2022
- Accession no.
- 0001209191-22-025515
- Filed
- Apr 25, 2022
- Trade date
- Apr 21-22, 2022
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 8 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.40M. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Wolchko J ScottCIK 0001586893 | Director, Officer (President and CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | MOption exerciseAcquired | +30,000 | $2.70 | +$81,000 | 461,546 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −22,715 | $34.57F2 | −$785,257.55 | 438,831 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −4,062 | $35.73F3 | −$145,135.26 | 434,769 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −2,220 | $36.70F4 | −$81,474 | 432,549 | Direct | |
| Apr 21, 2022 | Common Stock | SSaleDisposed | −1,003 | $37.90F5 | −$38,013.7 | 431,546 | Direct | |
| Apr 22, 2022 | Common Stock | MOption exerciseAcquired | +10,000 | $2.70 | +$27,000 | 441,546 | Direct | |
| Apr 22, 2022 | Common Stock | SSaleDisposed | −9,162 | $34.54F6 | −$316,455.48 | 432,384 | Direct | |
| Apr 22, 2022 | Common Stock | SSaleDisposed | −838 | $35.15F7 | −$29,455.7 | 431,546 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 21, 2022 | Common Stock | MOption exerciseDisposed | −30,000 | $2.70 | −$81,000 | 46,246 | Direct | |
| Apr 22, 2022 | Common Stock | MOption exerciseDisposed | −10,000 | $2.70 | −$27,000 | 36,246 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
Represents the weighted average sale price of the shares sold from $34.22 to $35.14 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7.
Referenced by the price of 1 transaction in Table I.
- F3
Represents the weighted average sale price of the shares sold from $35.29 to $36.25 per share.
Referenced by the price of 1 transaction in Table I.
- F4
Represents the weighted average sale price of the shares sold from $36.29 to $37.08 per share.
Referenced by the price of 1 transaction in Table I.
- F5
Represents the weighted average sale price of the shares sold from $37.70 to $38.38 per share.
Referenced by the price of 1 transaction in Table I.
- F6
Represents the weighted average sale price of the shares sold from $34.04 to $35.03 per share.
Referenced by the price of 1 transaction in Table I.
- F7
Represents the weighted average sale price of the shares sold from $35.04 to $35.29 per share.
Referenced by the price of 1 transaction in Table I.